Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adecatumumab - Amgen/Merck Serono

Drug Profile

Adecatumumab - Amgen/Merck Serono

Alternative Names: Anti-EpCAM mAb MT201; Human anti-EpCAM monoclonal antibody MT201; Monoclonal antibody MT201; MT 201; MT201 antibody

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Micromet Inc
  • Developer Amgen; Merck Serono
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epithelial cell adhesion molecule inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Prostate cancer

Most Recent Events

  • 07 Mar 2012 Micromet Inc has been acquired by Amgen
  • 10 Nov 2011 Micromet completes a phase II trial in Colorectal cancer in France and Germany (NCT00866944)
  • 04 Oct 2010 Adecatumumab is still in phase I trials for Breast cancer (combination therapy) in Austria and Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top